Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants

Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants

Primary: Progression at 6 Months — 11; 7 Participants

Primary: Change Rate of Prostate-specific Antigen (PSA) < Nadir + 2 ng/mL From First Day of Treatment to 15 Months (Cohort 2) — 100; 100 percentage of participants

Primary: Number of Participants With PSA < 0.6 ng/mL — 5 Participants

Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants

Primary: Participants With Greater Than or Equal to 50% Induction in Serum PAR4 Levels — 11 Participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Median Duration of Response — NA; NA months

Primary: Progression-free Survival — 10.5; 11.8 Months

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: Time to Progression — 11.2 weeks

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: The Number of Patients Who Demonstrate Pelvic Lymph Node Metastases on PSMA-PET/MRI That Were Not Detected on MRI — 3 Participants

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants

Primary: Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy) — 36.4; 44.2; 47.1 Gray (Gy)

Primary: Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. — 16 Participants

Primary: Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) — 0; 1; 1 dose-limiting toxicities

Primary: Median Progression-Free Survival (PFS) — 6.0 months — p=0.001

Primary: Undetectable PSA Rate — 42; 34 participants — p=0.16

Primary: Progression-free Survival — 11.2 months

Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants